These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS; Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461 [TBL] [Abstract][Full Text] [Related]
9. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Panza F; Logroscino G; Imbimbo BP; Solfrizzi V Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Salloway S; Sperling R; Gilman S; Fox NC; Blennow K; Raskind M; Sabbagh M; Honig LS; Doody R; van Dyck CH; Mulnard R; Barakos J; Gregg KM; Liu E; Lieberburg I; Schenk D; Black R; Grundman M; Neurology; 2009 Dec; 73(24):2061-70. PubMed ID: 19923550 [TBL] [Abstract][Full Text] [Related]
12. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR; N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891 [TBL] [Abstract][Full Text] [Related]
13. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Kaufer D; Gandy S Neurology; 2009 Dec; 73(24):2052-3. PubMed ID: 19923549 [No Abstract] [Full Text] [Related]
14. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. Novak G; Fox N; Clegg S; Nielsen C; Einstein S; Lu Y; Tudor IC; Gregg K; Di J; Collins P; Wyman BT; Yuen E; Grundman M; Brashear HR; Liu E J Alzheimers Dis; 2016; 49(4):1123-34. PubMed ID: 26639957 [TBL] [Abstract][Full Text] [Related]
15. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Ivanoiu A; Pariente J; Booth K; Lobello K; Luscan G; Hua L; Lucas P; Styren S; Yang L; Li D; Black RS; Brashear HR; McRae T Alzheimers Res Ther; 2016 Jun; 8(1):24. PubMed ID: 27334799 [TBL] [Abstract][Full Text] [Related]
17. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765 [TBL] [Abstract][Full Text] [Related]
19. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Li Y; Liu Y; Wang Z; Jiang Y Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611 [TBL] [Abstract][Full Text] [Related]
20. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? Panza F; Solfrizzi V; Imbimbo BP; Logroscino G Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]